Incyte Expands AI Drug Discovery With Genesis
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...
INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...
WALNUT CREEK, CA, USA & SUZHOU, CHINA, April 27, 2026 Dark Horse Consulting Group (DHCG) and Porton Advanced have...
BASKING RIDGE, N.J. and RAHWAY, N.J., September 15, 2025 – Daiichi Sankyo and Merck (known as MSD outside the...
